Mist from stem cell byproducts for autoimmune lung disease
Part of Lungs & breathing clinical trials.
This study tests a new type of treatment using a mist (nebulized) made from stem cell byproducts to see if it can safely help people with a rare autoimmune lung disease. It is for patients with anti-MDA5 positive dermatomyositis who have a fast-progressing lung condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific type of autoimmune disease called anti-MDA5 positive dermatomyositis, which affects your skin and muscles.
- You have a fast-worsening lung condition linked to your disease, known as rapidly progressive interstitial lung disease (RP-ILD).
- You are not pregnant or breastfeeding, and if you are a man, you agree to use birth control during the study.
- You do not have a severe lung infection, collapsed lung, or large fluid buildup around your lungs right now.
- You are not on a breathing tube ventilator or on advanced life support machines (like ECMO or dialysis for blood filtering).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how the immune system and tiny organisms in the lungs may affect a rare condition called anti-MDA5 positive dermatomyositis, which can cause serious lung disease. It may help doctors understand why some patients get worse quickly and how to better treat them.
This trial tests an investigational stem cell therapy (JadiCell) for patients with ARDS, a severe lung condition. The treatment aims to reduce lung inflammation and help you recover.
This trial tests whether combining two drugs, rituximab and mycophenolate mofetil, is safe and works better than standard care for lung scarring caused by scleroderma. It may be an option if your lung disease is severe or getting worse.
This trial tests whether a special type of stem cells from umbilical cords can help people with scleroderma-related lung disease that is getting worse. You may qualify if your lung function has declined despite current treatments.
This trial tests if adding the drug tocilizumab to standard therapy helps people with a rare type of dermatomyositis (anti-MDA5 positive) that often affects the lungs. It compares tocilizumab to a placebo to see if it can improve symptoms and lung function.
This study tests a new medicine called nerandomilast to see if it can help people with lung scarring caused by autoimmune rheumatic diseases like rheumatoid arthritis or scleroderma. The goal is to slow down lung damage and improve breathing.
Hear when a new Anti-MDA5 Positive Dermatomyositis-Associated RP-ILD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.